210 related articles for article (PubMed ID: 27065874)
1. The Anti-fibrotic Actions of Relaxin Are Mediated Through a NO-sGC-cGMP-Dependent Pathway in Renal Myofibroblasts In Vitro and Enhanced by the NO Donor, Diethylamine NONOate.
Wang C; Kemp-Harper BK; Kocan M; Ang SY; Hewitson TD; Samuel CS
Front Pharmacol; 2016; 7():91. PubMed ID: 27065874
[TBL] [Abstract][Full Text] [Related]
2. Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS.
Chow BS; Chew EG; Zhao C; Bathgate RA; Hewitson TD; Samuel CS
PLoS One; 2012; 7(8):e42714. PubMed ID: 22936987
[TBL] [Abstract][Full Text] [Related]
3. The anti-fibrotic actions of relaxin are mediated through AT
Wang C; Pinar AA; Widdop RE; Hossain MA; Bathgate RAD; Denton KM; Kemp-Harper BK; Samuel CS
FASEB J; 2020 Jun; 34(6):8217-8233. PubMed ID: 32297670
[TBL] [Abstract][Full Text] [Related]
4. Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling.
Sassoli C; Chellini F; Pini A; Tani A; Nistri S; Nosi D; Zecchi-Orlandini S; Bani D; Formigli L
PLoS One; 2013; 8(5):e63896. PubMed ID: 23704950
[TBL] [Abstract][Full Text] [Related]
5. Involvement of cyclic GMP and potassium channels in relaxation evoked by the nitric oxide donor, diethylamine NONOate, in the rat small isolated mesenteric artery.
Sampson LJ; Plane F; Garland CJ
Naunyn Schmiedebergs Arch Pharmacol; 2001 Sep; 364(3):220-5. PubMed ID: 11521164
[TBL] [Abstract][Full Text] [Related]
6. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis.
Hewitson TD; Mookerjee I; Masterson R; Zhao C; Tregear GW; Becker GJ; Samuel CS
Endocrinology; 2007 Feb; 148(2):660-9. PubMed ID: 17095590
[TBL] [Abstract][Full Text] [Related]
7. Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2.
Mookerjee I; Hewitson TD; Halls ML; Summers RJ; Mathai ML; Bathgate RA; Tregear GW; Samuel CS
FASEB J; 2009 Apr; 23(4):1219-29. PubMed ID: 19073841
[TBL] [Abstract][Full Text] [Related]
8. Cyclic guanosine monophosphate dependent pathway contributes to human mast cell inhibitory actions of the nitric oxide donor, diethylamine NONOate.
Yip KH; Huang Y; Leung FP; Lau HY
Eur J Pharmacol; 2010 Apr; 632(1-3):86-92. PubMed ID: 20096283
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the vasorelaxant effects of 3-(5'-hydroxymethyl-2'-furyl)-1-benzyl indazole (YC-1) and diethylamine/nitric oxide (DEA/NO) on the human radial artery used as coronary bypass graft.
Berkan O; Bagcivan I; Kaya T; Yildirim K; Yildirim S; Doğan K
Can J Physiol Pharmacol; 2007 May; 85(5):521-6. PubMed ID: 17632587
[TBL] [Abstract][Full Text] [Related]
10. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
11. Relaxin Affects Smooth Muscle Biophysical Properties and Mechanical Activity of the Female Mouse Colon.
Squecco R; Garella R; Idrizaj E; Nistri S; Francini F; Baccari MC
Endocrinology; 2015 Dec; 156(12):4398-410. PubMed ID: 26360621
[TBL] [Abstract][Full Text] [Related]
12. Relaxin Can Mediate Its Anti-Fibrotic Effects by Targeting the Myofibroblast NLRP3 Inflammasome at the Level of Caspase-1.
Pinar AA; Yuferov A; Gaspari TA; Samuel CS
Front Pharmacol; 2020; 11():1201. PubMed ID: 32848798
[TBL] [Abstract][Full Text] [Related]
13. The anti-fibrotic hormone relaxin is not reno-protective, despite being active, in an experimental model of type 1 diabetes.
Wong SE; Samuel CS; Kelly DJ; Zhang Y; Becker GJ; Hewitson TD
Protein Pept Lett; 2013 Sep; 20(9):1029-38. PubMed ID: 23343143
[TBL] [Abstract][Full Text] [Related]
14. The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway.
Heeg MH; Koziolek MJ; Vasko R; Schaefer L; Sharma K; Müller GA; Strutz F
Kidney Int; 2005 Jul; 68(1):96-109. PubMed ID: 15954899
[TBL] [Abstract][Full Text] [Related]
15. The Potential of sGC Modulators for the Treatment of Age-Related Fibrosis: A Mini-Review.
Sandner P; Berger P; Zenzmaier C
Gerontology; 2017; 63(3):216-227. PubMed ID: 27784018
[TBL] [Abstract][Full Text] [Related]
16. H3 relaxin demonstrates antifibrotic properties via the RXFP1 receptor.
Hossain MA; Man BC; Zhao C; Xu Q; Du XJ; Wade JD; Samuel CS
Biochemistry; 2011 Mar; 50(8):1368-75. PubMed ID: 21229994
[TBL] [Abstract][Full Text] [Related]
17. The effect of 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) and charybdotoxin (CTX) on relaxations of isolated cerebral arteries to nitric oxide.
Onoue H; Katusic ZS
Brain Res; 1998 Feb; 785(1):107-13. PubMed ID: 9526059
[TBL] [Abstract][Full Text] [Related]
18. Investigation of the role of the NO-cGMP pathway on YC-1 and DEA/NO effects on thoracic aorta smooth muscle responses in a rat preeclampsia model.
Turgut NH; Temiz TK; Turgut B; Karadas B; Parlak M; Bagcivan I
Can J Physiol Pharmacol; 2013 Oct; 91(10):797-803. PubMed ID: 24144050
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological characterisation of the relaxation induced by the soluble guanylate cyclase activator, BAY 60-2770 in rabbit corpus cavernosum.
Estancial CS; Rodrigues RL; De Nucci G; Antunes E; Mónica FZ
BJU Int; 2015 Oct; 116(4):657-64. PubMed ID: 25715977
[TBL] [Abstract][Full Text] [Related]
20. Matrix metalloproteinase-2 activity, protein, mRNA, and tissue inhibitors in small arteries from pregnant and relaxin-treated nonpregnant rats.
Jeyabalan A; Kerchner LJ; Fisher MC; McGuane JT; Doty KD; Conrad KP
J Appl Physiol (1985); 2006 Jun; 100(6):1955-63. PubMed ID: 16484357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
